Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 25: 83-86, 1979;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Christophidis, N.
Right arrow Articles by Louis, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christophidis, N.
Right arrow Articles by Louis, W.

Clinical Chemistry, Vol 25, 83-86, Copyright © 1979 by American Association for Clinical Chemistry

Comparison of liquid- and gas-liquid chromatographic assays of 5- fluorouracil in plasma

N Christophidis, G Mihaly, F Vajda and W Louis

A liquid-chromatographic assay of 5-fluorouracil in plasma is described. Advantages of this procedure over gas chromatography are the simpler extraction procedure, elimination of the need for a derivitization step with silylating agents, and a 20-fold greater sensitivity. The minimum detectable concentration of 5-fluorouracil in plasma is 25 microgram/L. The enhanced sensitivity enabled measurement of the concentrations of 5-fluorouracil found in plasms of patients receiving continuous intravenous infusions of the drug; such concentrations are generally unmeasurable by gas-chromatographic methods. We compared liquid-chromatographic and gas-chromatographic measurements on 36 plasma samples obtained from patients after rapid intravenous injection of 5-fluorouracil. The resulting correlation coefficient was 0.97, with a regression slope of 0.94. The liquid- chromatographic method is free of interference from other cytotoxic agents, anti-emetics, and folate derivatives that are frequently combined with 5-fluorouracil therapy.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Cancer Res.Home page
E. Van Den Neste, Dominique de Valeriola, J. Kerger, H. Bleiberg, Z. Kusenda, C. Brassinne, S. Bartholomeus, J. Selleslags, P. Hennebert, H. Wythouck, et al.
A Phase I and Pharmacokinetic Study of Docetaxel Administered in Combination with Continuous Intravenous Infusion of 5-Fluorouracil in Patients with Advanced Solid Tumors
Clin. Cancer Res., January 1, 2000; 6(1): 64 - 71.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
V. Pierrefite-Carle, P. Baque, A. Gavelli, M. Mala, M. Chazal, J. Gugenheim, A. Bourgeon, G. Milano, P. Staccini, and B. Rossi
Cytosine Deaminase/5-Fluorocytosine-Based Vaccination Against Liver Tumors: Evidence of Distant Bystander Effect
J Natl Cancer Inst, December 1, 1999; 91(23): 2014 - 2019.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. R. Adams, J. J. Leffert, D. J. Craig, T. Spector, and G. Pizzorno
In Vivo Effect of 5-Ethynyluracil on 5-Fluorouracil Metabolism Determined by 19F Nuclear Magnetic Resonance Spectroscopy
Cancer Res., January 1, 1999; 59(1): 122 - 127.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1979 by the American Association for Clinical Chemistry.